肿瘤免疫治疗的进展：肿瘤过继性免疫治疗的策略与创新策略

Cancer immunotherapy has emerged as a transformative approach in oncology, offering alternatives beyond traditional treatments. This narrative review focuses on major innovations, including adoptive cell therapy (ACT), chimeric antigen receptor T-cells (CAR-T), T-cell receptor (TCR) engineering, monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs). The central aim of this article is to analyze how these technologies improve antitumor responses and help overcome resistance in hematologic and solid tumors.

This narrative review combines the latest findings from clinical and preclinical studies to highlight therapeutic potentials and challenges. Key observations include the clinical success of CAR-T cells in treating blood cancers, the expanding application of ICIs in solid tumors, and the evolving structure-function relationship of BsAbs in recruiting immune effectors. This paper concludes by evaluating the current limitations of these immunotherapeutic strategies and discusses future directions for integrating them into personalized cancer therapy.